ABN AMRO Bank N.V. Purchases 490,983 Shares of Boston Scientific Corporation $BSX

Key Points

• ABN AMRO Bank N.V. significantly increased its stake in Boston Scientific, buying 490,983 additional shares in the fourth quarter and boosting its position by 597.3% to 573,182 shares worth about $54.6 million.
• Boston Scientific reported better-than-expected quarterly results, with EPS of $0.80 versus $0.79 expected and revenue of $5.20 billion, up 11.6% year over year. The company also raised guidance for Q2 2026 and FY 2026.
• Despite the positive earnings and analyst support, BSX shares were trading near their 52-week low at about $53.89, and several brokers had recently trimmed price targets even as the consensus rating remained Moderate Buy.

ABN AMRO Bank N.V. lifted its position in shares of Boston Scientific Corporation (NYSE:BSX - Free Report) by 597.3% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 573,182 shares of the medical equipment provider's stock after acquiring an additional 490,983 shares during the period. ABN AMRO Bank N.V.'s holdings in Boston Scientific were worth $54,563,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Murphy & Mullick Capital Management Corp lifted its holdings in shares of Boston Scientific by 200.0% during the 3rd quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider's stock worth $25,000 after acquiring an additional 170 shares during the period. FWL Investment Management LLC bought a new position in Boston Scientific in the 2nd quarter valued at approximately $26,000. United Community Bank lifted its stake in Boston Scientific by 115.7% in the 3rd quarter. United Community Bank now owns 274 shares of the medical equipment provider's stock valued at $27,000 after purchasing an additional 147 shares during the last quarter. Colonial Trust Co SC lifted its stake in Boston Scientific by 502.2% in the 3rd quarter. Colonial Trust Co SC now owns 277 shares of the medical equipment provider's stock valued at $27,000 after purchasing an additional 231 shares during the last quarter. Finally, Bangor Savings Bank lifted its stake in Boston Scientific by 94.7% in the 4th quarter. Bangor Savings Bank now owns 292 shares of the medical equipment provider's stock valued at $28,000 after purchasing an additional 142 shares during the last quarter. Institutional investors own 89.07% of the company's stock.

Boston Scientific Trading Down 0.1%

Shares of NYSE BSX opened at $53.89 on Monday. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.22 and a current ratio of 1.90. Boston Scientific Corporation has a 52-week low of $53.63 and a 52-week high of $109.50. The firm has a 50 day moving average price of $65.95 and a two-hundred day moving average price of $83.68. The stock has a market cap of $80.08 billion, a P/E ratio of 22.55, a price-to-earnings-growth ratio of 0.99 and a beta of 0.62.

Boston Scientific (NYSE:BSX - Get Free Report) last announced its quarterly earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.79 by $0.01. Boston Scientific had a net margin of 17.29% and a return on equity of 19.17%. The firm had revenue of $5.20 billion during the quarter, compared to analysts' expectations of $5.19 billion. During the same period in the prior year, the company posted $0.75 EPS. The company's revenue was up 11.6% on a year-over-year basis. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. As a group, equities analysts forecast that Boston Scientific Corporation will post 3.38 EPS for the current year.

Analyst Upgrades and Downgrades

Several brokerages recently commented on BSX. Sanford C. Bernstein reissued an "outperform" rating and issued a $112.00 price objective on shares of Boston Scientific in a research note on Friday, February 6th. Stifel Nicolaus dropped their price objective on shares of Boston Scientific from $90.00 to $85.00 and set a "buy" rating for the company in a research note on Tuesday, April 21st. Robert W. Baird dropped their price objective on shares of Boston Scientific from $86.00 to $78.00 and set an "outperform" rating for the company in a research note on Thursday, April 23rd. JPMorgan Chase & Co. dropped their price objective on shares of Boston Scientific from $135.00 to $100.00 and set an "overweight" rating for the company in a research note on Thursday, February 5th. Finally, Raymond James Financial reissued an "outperform" rating and issued a $88.00 price objective (down from $97.00) on shares of Boston Scientific in a research note on Monday, March 30th. One analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $93.91.

Boston Scientific Profile

Boston Scientific Corporation NYSE: BSX is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific's activities span product development, clinical research, regulatory affairs and commercial sales.

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.